The Effect of ZD 1839 (IressaⓇ) in the Treatment of Refractory Non Small Cell Lung Cancer
Authors
Yong Tai Kim ; Chul Kim ; Joo Hang Kim ; Kyung Young Chung ; Kil Dong Kim ; Joon Chang ; Se Kyu Kim ; Young Sam Kim ; Nae Choon Yu ; Soo Young Park ; So Young Park ; Joo Hyuk Sohn
Citation
CANCER RESEARCH AND TREATMENT, Vol.35(6) : 502-506, 2003
PURPOSE: The aim of this study was to evaluate the efficacy and the safety of ZD 1839 (IressaⓇ) as a 3rd or 4th line chemotherapy regimen in NSCLC patients who are refractory to a previous chemotherapy regimen. MATERIALS AND METHODS: Twenty-five patients who were refractory to previous chemotherapy were selected for this study. The eligible patients had an ECOG performance status of 0 to 2, and an appropriate end organ function. ZD 1839 (IressaⓇ)250 mg/d was orally administered until the patients experienced disease progression or unacceptable toxicity. RESULTS: Twenty-five patients were analyzed. The median age of the patients was 57 years. The response rate was 12.0% with partial responses in 3 patients. Fourteen patients (56%) remained in the stable disease state and 8 patients progressed. The median overall survival was 9.0 months (95% CI 6.7~11.2). The median progression free survival was 3 months (95% CI 2.2~3.8). Hematological toxicities of grade 3 or 4 neutropenia, anemia and thrombocytopenia were absent. Non-hematological toxicities were grade 2 or 3 skin rashes in 10 (40.0%) patients and 1 (4.0%) patient and grade 3 nausea in 3 (12.0%) patients. No patient failed to continue chemotherapy due to any drug-related adverse events. CONCLUSION: The results suggest that ZD 1839 (IressaⓇ) monotherapy is effective and tolerable as a 3rd or 4th line salvage treatment for NSCLC patients refractory to previous chemotherapy regimens.